News room
TZ-161 one step closer to clinical trials in spinal cord injury
Technophage is thrilled to share that TZ-161 product is now one step closer to potentially becoming a pioneering repurposed treatment for patients...
Miguel Garcia unveils plans for the Bio-Hub Agenda at the First Annual Meeting
Miguel Garcia, the CEO of Technophage S.A. and LxBio - Pharmaceuticals S.A., recently presented the Bio-Hub Project during the First Annual Meeting...
Annual Teambuilding event celebrated in the picturesque town of Dornes
This week marked an important occasion as Technophage and VectorB2B - Drug Development joined forces for our annual Teambuilding event. Our...
TP-102 clinical trial presented at ECCMID 2023
Last month Technophage team attended 33rd European Congress of Clinical Microbiology & Infectious Diseases with the clinical team from Israel,...
Technophage featured in ‘The Economist’
Technophage has been featured in 'The Economist' journal. The piece entitled ‘Western firms are becoming interested in a Soviet medicine’ describes...